Rising Rupee Cuts Into Nicholas Piramal Revenues
This article was originally published in PharmAsia News
NEW DELHI - Mumbai-based Nicholas Piramal has lowered its revenue forecast in the current financial year because of rapid gains by the rupee against the dollar and pledged to cut low-margin products from its portfolio to ensure net profit would meet target
You may also be interested in...
Mumbai-based Nicholas Piramal India Limited inked a research and development deal with Delhi-based Merck subsidiary MSD Pharmaceuticals, NPIL announced Nov. 19
Lilly's research and development agreement with India-based Nicholas Piramal India Limited gives the Indian firm the potential to earn $100 million in milestones and call-back payments, the firms said Jan. 12
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).